Bringing the fundamentals into focus…
Back to Protagonist Therapeutics, Inc.
How Protagonist Therapeutics, Inc. stacks up
PTGX · against 177 other Healthcare companies of similar size
Valuation
38/ 100
Near the bottom of its peers.
Ranked #132 of 178 · scores higher than 25% of peers
Bars: peers in each 10-point band of the valuation score15 peers with a valuation score of 30–39, including PTGX · Click a bar to see the companies
Why valuation scores 38?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 65% of peers. EBITDA yield: 0.7% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 0.9% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.4% vs peer median 0.0%
Metric by metric
Position: dot = PTGX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PTGX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 177 reported | 0.7% | 2.5% | 30% | 30% | |
| EBITDA yieldHigher is better · 177 reported | 0.7% | 4.7% | 22% | 50% | |
| Free cash flow yieldHigher is better · 105 reported | 1.4% | 1.8% | 47% | 20% | |
| Book yieldHigher is better · 177 reported | 9.3% | 19.5% | 23% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PTGX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 130 | 138.4B HKD (≈$17.7B) | 39 | 70 | |
| 130 | 9.4B USD | 39 | 70 | |
| 132 | 1.26T INR (≈$15.1B) | 38 | 63 | |
| 132 | 20.0B AUD (≈$13.2B) | 38 | 77 | |
| 132 | 9.1B USD | 38 | 74 | |
| 135 | 14.87T KRW (≈$10.7B) | 37 | 76 | |
| 135 | 5.2B USD | 37 | 74 | |
| 135 | 8.6B USD | 37 | 30 | |
| 135 | 10.1B USD | 37 | 61 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score